Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37435600 | 1.00 | CYP1A2 (0.36) | CYP1A2CYP2D6KDM4ENPC1ALDH1A1 | |
| SCHEMBL4891879 | 0.70 | TRPA1 (0.40) | TRPA1 | |
| SCHEMBL15549945 | 0.70 | KDM4E (0.36) | CYP1A2CYP2D6KDM4ENPC1ALDH1A1 | |
| SCHEMBL29870245 | 0.70 | CYP1A2 (0.41) | CYP1A2CYP2D6KDM4ENPC1ALDH1A1 | |
| SCHEMBL17732176 | 0.69 | CYP1A2 (0.36) | CYP1A2CYP2D6KDM4ENPC1ALDH1A1 | |
| SCHEMBL12373082 | 0.69 | TRPA1 (0.34) | KDM4EALDH1A1MAPTPPARATRPA1 | |
| SCHEMBL1357123 | 0.68 | IDO1 (0.31) | — | |
| SCHEMBL38660406 | 0.68 | ALDH1A1 (0.35) | KDM4EALDH1A1GAAMAPT | |
| SCHEMBL9461527 | 0.67 | PPARA (0.31) | PPARA | |
| SCHEMBL8587215 | 0.66 | LMNA (0.50) | KDM4ENPC1ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0767809-B1 | CURE-INDICATING MOLDING AND COATING COMPOSITION | MINNESOTA MINING & MFG (US) | 2004-01-21 | — | — | EP | claimed |
| WO-2026102344-A2 | NEAR INFRARED FLUOROPHORES FOR PERIPHERAL AND CENTRAL NERVE IMAGING | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-115372324-A | Detection method and detection reagent for phenylalanine | 中国科学院理化技术研究所 | 2022-11-22 | — | — | CN | disclosed |
| CN-110914328-B | Indicator system | 科思创德国股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-110945048-B | Acidic indicator system | 科思创德国股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3668914-A1 | INDICATOR SYSTEM | Covestro Deutschland AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668913-A1 | ACID INDICATOR SYSTEM | Covestro Deutschland AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| CN-110301052-A | Photo-electric conversion element and optical region sensor, image pick-up element and the image pick up equipment for using it | 佳能株式会社 | 2019-10-01 | — | — | CN | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| CN-101440282-B | Near-infrared fluorescent molecular probe, synthesizing method and use thereof | UNIV CHINA PHARMA | 2012-06-27 | — | — | CN | disclosed |
| US-20070031336-A1 | 3H-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| EP-1713457-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-10-25 | — | — | EP | disclosed |
| CN-1835955-A | 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof | NOVARTIS AG (CH) | 2006-09-20 | — | — | CN | disclosed |
| CN-1835955-A | 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof | NOVARTIS AG (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1679508-A1 | BIOSENSOR AND METHOD FOR PREPARATION THEREOF | Arkray, Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-1658294-A1 | 3H-PHENOXAZINE DERIVATIVES SUITABLE AS NEAR-INFRARED IMAGING AGENTS, PREPARATION AN USE THEREOF | Novartis AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005077343-A9 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX DELBRUECK CENTRUM (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005077343-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005016934-A1 | 3H-PHENOXAZINE DERIVATIVES SUITABLE AS NEAR-INFRARED IMAGING AGENTS, PREPARATION AN USE THEREOF | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-5498542-A | Electrode mediators for regeneration of NADH and NADPH | BAYER CORPORATION (US) | 1996-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070031336-A1 | 3H-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof | PSEN1, PSEN2, CHRM5 | CYP1A2 238/4885CYP2D6 488/4885KDM4E 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.